Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Today’s Research Excellence Framework (REF 2014) results confirm the University of Oxford’s world leading position in medical sciences research.

We ranked top for the overall quality of our submissions in the following three areas: Clinical Medicine; Public Health, Health Service and Primary Care; and also in Psychology, Psychiatry and Neuroscience.

Within Biological Science, Oxford produced the largest volume of world leading and internationally excellent research in the exercise.  

The University is also rated top in the REF power rankings published by Research Fortnight, and overall has the largest volume of world leading research and impact submitted to the REF exercise.

Read more on the University of Oxford website

REF 2014 Results table  

 

Further coverage

Times Higher Education REF 2014: Results by Subject

Oxford overtakes Cambridge as Britain's top research university (The Guardian)

REF Power Rankings (Research Fortnight - pdf)

Similar stories

Promising discovery for treatment of neuromuscular diseases

Research led by Carlo Rinaldi and Catheryn Lim discovered that a naturally-occurring isoform of an androgen receptor can be used in therapy for spinal and bulbar muscular atrophy, and shows potential for other diseases.

University of Oxford researchers among recipients of Ireland and UK joint research awards for digital humanities in €6.5m boost for interdisciplinary research partnerships

Dr Samantha Vanderslott (Oxford Vaccine Group) and Dr Claas Kirchhelle (University College Dublin) have had their three-year project ‘Typhoid, Cockles, and Terrorism’ about the history of typhoid in Dublin successfully funded.

The Oxford-Harrington Rare Disease Centre initiates first disease priority area: Friedreich’s Ataxia

The Oxford-Harrington Rare Disease Centre is redoubling efforts to develop a therapeutics programme for Friedreich’s Ataxia.

Why we must expand newborn screening

Early diagnosis is of primary importance both to obtain the best effect of innovative medications and to accelerate their development, writes Professor Laurent Servais.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK

A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants.